摘要
目的:评价黄芪注射液联合复方丹参注射液治疗慢性心力衰竭的临床疗效及安全性。方法:计算机检索CNKI、万方数据库、超星数字图书、VIP、CBMdisk、Pubmed、Elsevier期刊全文数据库、Sci Finder数据库、Web of science数据库及Cochrane library有关黄芪注射液联合复方丹参注射液治疗慢性心力衰竭的研究。采用Revman 5.3软件对纳入的RCT的临床疗效、左室射血分数(LVEF%)、心输出量(CO)、心脏指数(CI)、每搏输出量(SV)等进行Meta分析。结果:纳入9个RCT试验,共700例CHF患者,文献质量普遍偏低。结果显示,在西医常规治疗基础上加用黄芪注射液联合复方丹参注射液可显著提高临床疗效[WMD=4.70,95%CI(2.88,7.66),P<0.00001],增加LVEF[WMD=6.38,95%CI(2.18,10.58),P=0.003]、CO[WMD=0.43,95%CI(0.36,0.49),P<0.00001]、CI[WMD=0.46,95%CI(0.22,0.69),P=0.0001]及SV[WMD=10.0,95%CI(0.63,19.38),P=0.04],且不良反应较少,未见其他毒副作用,安全性良好。结论:在西医常规治疗基础上加用黄芪注射液联合复方丹参注射液治疗慢性心力衰竭安全、有效、副作用少。
Objective： To estimate the clinical efficacy and safety of Astragalus injection combined with Fufang danshen injection （复方丹参注射液, FFDSI） in the treatment of chronic heart failure. Methods： We searched in the CNKI, Wanfang Data, Superstar Digital Deficiency, VIP database, CBMdisk, Pubmed, Elsevier Data, SciFinder Data, Web of science Data and Cochrane library to identify studies on the clinical efficacy and safety of Astragalus injection combined with FFDSI in the treatment of chronic heart failure based on the western medicine routine treatment. The clinical efficacy, left ventricular ejection fraction （LVEF）,cardiac output （CO）, cardiac index （CI） and stroke volume （SV） of studies were analyzed by the Revman 5.3 software. Results： A total of 9 randomized controlled trials were reviewed, and 700 patients were included, the quality of involved studies was low. The analysis showed that： for patients with chronic heart failure who used Astragalus injection combined with FFDSI based on the western medicine routine treatment, clinical efficacy [WMD=4.70, 95%CI （2.88, 7.66）, P〈0.00001] improve significantly, LVEF [WMD=6.38, 95%CI（2.18, 10.58）, P=0.003], CO [WMD=0.43, 95%CI（0.36,0.49）, P〈0.00001], CI [WMD=0.46, 95%C1（0.22,0.69）, P=0.0001] and SV [WMD=10.0, 95%CI（0.63,19.38）, P=0.04] increased. The untoward effect was less and patients with untoward effect were all can tolerated. In addition, there were no other toxic and side effect. Therefore, Astragalus injection combined with FFDSI was safe. Conclusion： The use of Astragalus injection combined with FFDSI in the treatment of chronic heart failure based on the western medicine routine treatment is safe and reliable.
出处
《中医药导报》
2016年第24期62-68,共7页
Guiding Journal of Traditional Chinese Medicine and Pharmacy
基金
国家中医药管理局国家中医临床研究基地业务建设科研专项课题(JDZX2015149)
